Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

(2020) David J. Gibson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease

(2020) Peter Bossuyt et al.   Clinical Gastroenterology and Hepatology

Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease

(2019) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Infliximab therapy intensification upon loss of response: Is there an optimal trough level?

(2019) Bella Ungar et al.   DIGESTIVE AND LIVER DISEASE

Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment

(2019) Ting Feng et al.   INFLAMMATORY BOWEL DISEASES

Challenges in IBD Research: Pragmatic Clinical Research

(2019) Frank I Scott et al.   INFLAMMATORY BOWEL DISEASES

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring

(2019) Amit Assa et al.   GASTROENTEROLOGY

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

(2019) Nicholas A Kennedy et al.   Lancet Gastroenterology & Hepatology

Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels

(2019) Vasilije Novakovic et al.   CLINICAL BIOCHEMISTRY

Letter to the Editor: Feasibility and Efficiency of an E-Health Preadmission Assessment System for Intravenous Therapy in Inflammatory Bowel Disease

(2019) Lieven Pouillon et al.   INFLAMMATORY BOWEL DISEASES

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab

(2018) Lieven Pouillon et al.   Clinical Gastroenterology and Hepatology

Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD

(2018) Yara Nasser et al.   DIGESTIVE DISEASES AND SCIENCES

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

(2018) Geert D’Haens et al.   GASTROENTEROLOGY

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

(2018) Karen van Hoeve et al.   Journal of Crohns & Colitis

Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis

(2018) Niels Vande Casteele et al.   Clinical Gastroenterology and Hepatology

Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience

(2016) T. Billiet et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2016) Bella Ungar et al.   Clinical Gastroenterology and Hepatology

Pragmatic Trials

(2016) Ian Ford et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation

(2016) Thomas Van Stappen et al.   Clinical and Translational Gastroenterology

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease

(2013) Renathe Rismo et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE